leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...2829303132333435363738...235236»
  • ||||||||||  Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
    Associations between BMI, morphomics and survival in 528 patients with metastatic pancreatic cancer. (Poster Bd # K6) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_553;    
    BMI was not associated with PFS or OS in this large prospective study of patients with metastatic PDA receiving chemotherapy. However, morphomic variables including subcutaneous fat area, visceral fat density, and the muscle to fascia ratio were statistically significantly associated with metastatic PDA patient survival.
  • ||||||||||  tinengotinib (TT-00420) / TransThera Biosci
    First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor (Poster Bd # P4) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_353;    
    P1, P1/2,
    The first generation FGFR inhibitors (FGFRi) pemigatinib and futibatinib, have been approved for the treatment of advanced CCA with FGFR2 fusions or rearrangements after systemic chemotherapy...The study includes Part A and Part B. The Part A is to select a dose for Part B. Eligible subjects will be randomized in a 2:2:1 ratio to receive tinengotinib 8 mg QD, tinengotinib 10 mg QD or Physician's Choice (FOLFOX or FOLFIRI) in Part A or 2:1 in Part B to receive the recommended Part B dose or Physician's Choice...Study is open for enrollment. Clinical trial information: NCT05948475.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    PD1 and CD39 expression on tumor infiltrating lymphocytes in patients with gastric cancer. (Poster Bd # H19) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_260;    
    A randomized phase II study is planned using D to prevent OPIN. DP-TILs may have superior T cell receptors recognizing tumor-antigens and contribute to tumor eradication, especially when administrated anti-CD39 antibody.